FONT-SIZE Plus   Neg

Delcath Systems' Hepatic CHEMOSAT Delivery System Used First To Treat Patient

Specialty pharmaceutical company Delcath Systems Inc (DCTH) Friday revealed that the European Institute of Oncology, a premier cancer treatment and research center in Milan has performed the first treatment using the second generation hemofiltration cartridge of the Company's proprietary Hepatic CHEMOSAT Delivery System.

The company stated that a patient was treated for inoperable liver-dominant metastases from ocular melanoma, a case that represents the first use of the second generation hemofiltration cartridge in a clinical setting.

"We are pleased to finally be able to provide the second generation CHEMOSAT system to our early launch centers in Europe," said Eamonn P. Hobbs, President and CEO of Delcath Systems. "Now that we are beginning to treat patients with the new system, we are confident that efficiency data we've seen in our in vivo studies will be validated in actual clinical use. We are also pleased that the team at the IEO is the first to begin exploring the benefits of the new system, and look forward to working with them and other early launch centers to establish the benefits of this system for patients with cancers in the liver."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Baker Hughes Inc.'s shares gained around 7 percent in the extended trading on Thursday after conglomerate General Electric Co. confirmed, while responding to media reports, that it is in talks to buy the oilfield services provider. The stock is moving 6 percent ahead in the pre-market activity. Shares of Sanofi were gaining around 7 percent in the morning trading in Paris after the French drug maker on Friday raised its 2016 business earnings guidance, after it reported strong third-quarter results. In addition, the company set a 3.5 billion euros share repurchase program to be completed by the end of 2017. Swiss banking giant UBS Group AG (UBS) reported Friday an increased pre-tax profit for the third quarter despite weakness in net interest income. Net profit, however, decreased on the absence of last year's hefty tax benefit. Looking ahead, UBS said it is unlikely that the underlying macroeconomic uncertainty and geopolitical tensions will change in the foreseeable future.
comments powered by Disqus
Follow RTT